Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Macdonell

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Journal of Neurology|June 29, 2014
Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER studyAaron E Miller, Richard Macdonell, Giancarlo Comi, et al.
Epilepsy & Behavior : E&B|February 1, 2022
Electroclinical biomarkers of autoimmune encephalitisRobb Wesselingh, James Broadley, Katherine Buzzard, et al.
Journal of Neuroimmunology|February 15, 2021
Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitisJames Broadley, Robb Wesselingh, Udaya Seneviratne, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|December 9, 2022
Neuroimaging characteristics may aid in diagnosis, subtyping, and prognosis in autoimmune encephalitisJames Broadley, Robb Wesselingh, Paul Beech, et al.
Epilepsy & Behavior : E&B|May 27, 2022
Prevalence, risk factors, and prognosis of drug-resistant epilepsy in autoimmune encephalitisRobb Wesselingh, James Broadley, Katherine Buzzard, et al.
Neurology and Therapy|December 14, 2024
Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM StudyKrupa Shah Pandey, Kathryn Giles, Konstantin Balashov, et al.
BMJ Neurology Open|July 22, 2022
Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational dataTodd A Hardy, John Parratt, Heidi Beadnall, et al.
The Medical Journal of Australia|November 21, 2012
Guillain-Barré syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self-controlled case seriesNigel W Crawford, Allen Cheng, Nick Andrews, et al.
BMJ Open|March 10, 2026
Feasibility of an adjunctive INtervention for Debilitating symptom complexes attributed to ticks (FIND): study protocol for a randomised, waitlist-controlled feasibility trialRichard A A Kanaan, Richard Macdonell, Michelle Long, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 9, 2015
Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridineRichard Macdonell, Guy Nagels, David-Axel Laplaud, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Journal of Neurology|June 29, 2014
Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER studyAaron E Miller, Richard Macdonell, Giancarlo Comi, et al.
Epilepsy & Behavior : E&B|February 1, 2022
Electroclinical biomarkers of autoimmune encephalitisRobb Wesselingh, James Broadley, Katherine Buzzard, et al.
Journal of Neuroimmunology|February 15, 2021
Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitisJames Broadley, Robb Wesselingh, Udaya Seneviratne, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|December 9, 2022
Neuroimaging characteristics may aid in diagnosis, subtyping, and prognosis in autoimmune encephalitisJames Broadley, Robb Wesselingh, Paul Beech, et al.
Epilepsy & Behavior : E&B|May 27, 2022
Prevalence, risk factors, and prognosis of drug-resistant epilepsy in autoimmune encephalitisRobb Wesselingh, James Broadley, Katherine Buzzard, et al.
Neurology and Therapy|December 14, 2024
Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM StudyKrupa Shah Pandey, Kathryn Giles, Konstantin Balashov, et al.
BMJ Neurology Open|July 22, 2022
Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational dataTodd A Hardy, John Parratt, Heidi Beadnall, et al.
The Medical Journal of Australia|November 21, 2012
Guillain-Barré syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self-controlled case seriesNigel W Crawford, Allen Cheng, Nick Andrews, et al.
BMJ Open|March 10, 2026
Feasibility of an adjunctive INtervention for Debilitating symptom complexes attributed to ticks (FIND): study protocol for a randomised, waitlist-controlled feasibility trialRichard A A Kanaan, Richard Macdonell, Michelle Long, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 9, 2015
Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridineRichard Macdonell, Guy Nagels, David-Axel Laplaud, et al.
Pageof 6